![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sanofi, Biond Biologics Partner to Develop Cancer Drug
Sanofi, Biond Biologics Partner to Develop Cancer Drug
January 14, 2021
Israel-based Biond Biologics has signed a license agreement with Sanofi for the development and commercialization of BND-22, an investigational cancer treatment.
Biond will receive $125 million in cash up front and potentially more than $1 billion upon reaching development, regulatory and sales milestones, as well as royalty payments.
The company will lead an early-stage study of its antibody treatment as a single agent and in combination with approved cancer therapeutics. If the early research shows promise, Sanofi will take on the clinical development and commercialization responsibilities.
Upcoming Events
-
21Oct